247 related articles for article (PubMed ID: 33207027)
1. Filtering for the best policy: An economic evaluation of policy options for kidney replacement coverage in the Philippines.
Bayani DBS; Almirol BJQ; Uy GDC; Taneo MJS; Danguilan RS; Arakama MI; Lamban AB; de Leon D; Pamugas GEP; Luz AC; Teerawatananon Y
Nephrology (Carlton); 2021 Feb; 26(2):170-177. PubMed ID: 33207027
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation of palliative management versus peritoneal dialysis and hemodialysis for end-stage renal disease: evidence for coverage decisions in Thailand.
Teerawattananon Y; Mugford M; Tangcharoensathien V
Value Health; 2007; 10(1):61-72. PubMed ID: 17261117
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of policy options for dialysis in end-stage renal disease patients under the universal health coverage in Indonesia.
Afiatin ; Khoe LC; Kristin E; Masytoh LS; Herlinawaty E; Werayingyong P; Nadjib M; Sastroasmoro S; Teerawattananon Y
PLoS One; 2017; 12(5):e0177436. PubMed ID: 28545094
[TBL] [Abstract][Full Text] [Related]
4. Lifetime cost-effectiveness analysis of first-line dialysis modalities for patients with end-stage renal disease under peritoneal dialysis first policy.
Wong CKH; Chen J; Fung SKS; Mok M; Cheng YL; Kong I; Lo WK; Lui SL; Chan TM; Lam CLK
BMC Nephrol; 2020 Feb; 21(1):42. PubMed ID: 32019528
[TBL] [Abstract][Full Text] [Related]
5. Direct medical costs of end-stage kidney disease and renal replacement therapy: a cohort study in Guangzhou City, southern China.
Zhang H; Zhang C; Zhu S; Ye H; Zhang D
BMC Health Serv Res; 2020 Feb; 20(1):122. PubMed ID: 32059726
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of haemodialysis and peritoneal dialysis for patients with end-stage renal disease in Singapore.
Yang F; Lau T; Luo N
Nephrology (Carlton); 2016 Aug; 21(8):669-77. PubMed ID: 26566750
[TBL] [Abstract][Full Text] [Related]
7. Dialysis Care and Dialysis Funding in Asia.
Tang SCW; Yu X; Chen HC; Kashihara N; Park HC; Liew A; Goh BL; Nazareth MGC; Bunnag S; Tan J; Lun V; Lydia A; Sharma SK; Hoque E; Togtokh A; Ghnaimet M; Jha V
Am J Kidney Dis; 2020 May; 75(5):772-781. PubMed ID: 31699518
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of peritoneal dialysis and hemodialysis in Thai population with End-stage Kidney Disease.
Assanatham M; Pattanaprateep O; Chuasuwan A; Vareesangthip K; Supasyndh O; Lumpaopong A; Susantitaphong P; Limkunakul C; Ponthongmak W; Chaiyakittisopon K; Thakkinstian A; Ingsathit A
BMC Health Serv Res; 2022 Nov; 22(1):1384. PubMed ID: 36411422
[TBL] [Abstract][Full Text] [Related]
9. A call for harmonization of European kidney care: dialysis reimbursement and distribution of kidney replacement therapies.
van der Tol A; Stel VS; Jager KJ; Lameire N; Morton RL; Van Biesen W; Vanholder R
Nephrol Dial Transplant; 2020 Jun; 35(6):979-986. PubMed ID: 32227227
[TBL] [Abstract][Full Text] [Related]
10. Healthcare costs in chronic kidney disease and renal replacement therapy: a population-based cohort study in Sweden.
Eriksson JK; Neovius M; Jacobson SH; Elinder CG; Hylander B
BMJ Open; 2016 Oct; 6(10):e012062. PubMed ID: 27855091
[TBL] [Abstract][Full Text] [Related]
11. Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter?
Yang F; Devlin N; Luo N
Value Health; 2019 Jan; 22(1):45-49. PubMed ID: 30661633
[TBL] [Abstract][Full Text] [Related]
12. Hemodialysis versus peritoneal dialysis, which is cost-effective?
Atapour A; Eshaghian A; Taheri D; Dolatkhah S
Saudi J Kidney Dis Transpl; 2015 Sep; 26(5):962-5. PubMed ID: 26354569
[TBL] [Abstract][Full Text] [Related]
13. Financial implications of dialysis modalities in the developing world: A Chinese perspective.
Liu J; Hutton DW; Gu Y; Hu Y; Li Y; Ma L; Zeng X; Fu P
Perit Dial Int; 2020 Mar; 40(2):193-201. PubMed ID: 32063196
[TBL] [Abstract][Full Text] [Related]
14. Cost analysis of renal replacement therapy by transplant in a system of bundled payment of dialysis.
Rocha MJ; Ferreira S; Martins LS; Almeida M; Dias L; Pedroso S; Henriques AC; Almeida R; Cabrita A
Clin Transplant; 2012; 26(4):529-31. PubMed ID: 22211715
[TBL] [Abstract][Full Text] [Related]
15. Economic burden and cost-utility analysis of three renal replacement therapies in ESRD patients from Yunnan Province, China.
Wu H; Li Q; Cai Y; Zhang J; Cui W; Zhou Z
Int Urol Nephrol; 2020 Mar; 52(3):573-579. PubMed ID: 32009220
[TBL] [Abstract][Full Text] [Related]
16. Health economic evaluations: the special case of end-stage renal disease treatment.
Winkelmayer WC; Weinstein MC; Mittleman MA; Glynn RJ; Pliskin JS
Med Decis Making; 2002; 22(5):417-30. PubMed ID: 12365484
[TBL] [Abstract][Full Text] [Related]
17. Peritoneal dialysis vs. hemodialysis among patients with end-stage renal disease in Iran: which is more cost-effective?
Yousefi M; Rezaei S; Hajebrahimi S; Falsafi N; Keshvari-Shad F
BMC Nephrol; 2024 Mar; 25(1):85. PubMed ID: 38448887
[TBL] [Abstract][Full Text] [Related]
18. Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines.
Genuino AJ; Chaikledkaew U; Guerrero AM; Reungwetwattana T; Thakkinstian A
BMC Health Serv Res; 2019 Nov; 19(1):874. PubMed ID: 31752849
[TBL] [Abstract][Full Text] [Related]
19. Direct and indirect costs of end-stage renal disease patients in the first and second years after initiation of nocturnal home haemodialysis, hospital haemodialysis and peritoneal dialysis.
Wong CKH; Chen J; Fung SKS; Mok MMY; Cheng YL; Kong I; Lo WK; Lui SL; Chan TM; Lam CLK
Nephrol Dial Transplant; 2019 Sep; 34(9):1565-1576. PubMed ID: 30668781
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of end stage renal disease treatment.
de Wit GA; Ramsteijn PG; de Charro FT
Health Policy; 1998 Jun; 44(3):215-32. PubMed ID: 10182294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
